胰腺癌循环肿瘤细胞分离微流控和免疫磁性平台的标杆研究

IF 5.4 2区 工程技术 Q1 BIOCHEMICAL RESEARCH METHODS
Lab on a Chip Pub Date : 2025-08-28 DOI:10.1039/d5lc00512d
Celine Macaraniag, Ifra Khan, Alexandra Barabanova, Valentina Valle, Jian Zhou, Pier C. Giulianotti, Alain Borgeat, Gina Votta-Velis, Ian Papautsky
{"title":"胰腺癌循环肿瘤细胞分离微流控和免疫磁性平台的标杆研究","authors":"Celine Macaraniag, Ifra Khan, Alexandra Barabanova, Valentina Valle, Jian Zhou, Pier C. Giulianotti, Alain Borgeat, Gina Votta-Velis, Ian Papautsky","doi":"10.1039/d5lc00512d","DOIUrl":null,"url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality in the US., with poor prognosis due to late-stage diagnosis and high recurrence rates following surgery. Circulating tumor cells (CTCs) are thought to contribute to post-surgical metastasis, while circulating epithelial cells (CECs) have been detected in up to 33% of patients with premalignant pancreatic cysts, offering a potential window for early intervention. Despite their promise as prognostic biomarkers, the clinical utility of CTCs and CECs in pancreatic cancer remains underexplored. Microfluidic technologies offer label-free isolation of rare cells, but few have been benchmarked against clinically validated systems. In this study, we conducted a direct comparison of our inertial microfluidic system with a widely used immunomagnetic negative selection platform (EasySep™). Using matched experimental conditions, we quantified target cell recovery and enrichment to evaluate performance. The inertial microfluidic system demonstrated higher recovery and enrichment, particularly at low cell concentrations, compared to EasySep™, supporting its potential for clinical translation. These findings highlight the advantages of label-free microfluidic isolation and its promise for early detection, prognostic assessment, and therapeutic monitoring in pancreatic cancer.","PeriodicalId":85,"journal":{"name":"Lab on a Chip","volume":"70 1","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Benchmarking microfluidic and immunomagnetic platforms for isolating circulating tumor cells in pancreatic cancer\",\"authors\":\"Celine Macaraniag, Ifra Khan, Alexandra Barabanova, Valentina Valle, Jian Zhou, Pier C. Giulianotti, Alain Borgeat, Gina Votta-Velis, Ian Papautsky\",\"doi\":\"10.1039/d5lc00512d\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality in the US., with poor prognosis due to late-stage diagnosis and high recurrence rates following surgery. Circulating tumor cells (CTCs) are thought to contribute to post-surgical metastasis, while circulating epithelial cells (CECs) have been detected in up to 33% of patients with premalignant pancreatic cysts, offering a potential window for early intervention. Despite their promise as prognostic biomarkers, the clinical utility of CTCs and CECs in pancreatic cancer remains underexplored. Microfluidic technologies offer label-free isolation of rare cells, but few have been benchmarked against clinically validated systems. In this study, we conducted a direct comparison of our inertial microfluidic system with a widely used immunomagnetic negative selection platform (EasySep™). Using matched experimental conditions, we quantified target cell recovery and enrichment to evaluate performance. The inertial microfluidic system demonstrated higher recovery and enrichment, particularly at low cell concentrations, compared to EasySep™, supporting its potential for clinical translation. These findings highlight the advantages of label-free microfluidic isolation and its promise for early detection, prognostic assessment, and therapeutic monitoring in pancreatic cancer.\",\"PeriodicalId\":85,\"journal\":{\"name\":\"Lab on a Chip\",\"volume\":\"70 1\",\"pages\":\"\"},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2025-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lab on a Chip\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1039/d5lc00512d\",\"RegionNum\":2,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lab on a Chip","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1039/d5lc00512d","RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

摘要

胰腺导管腺癌(PDAC)是美国癌症相关死亡的第四大原因。诊断较晚,预后较差,术后复发率高。循环肿瘤细胞(ctc)被认为有助于手术后转移,而循环上皮细胞(CECs)在高达33%的癌前胰腺囊肿患者中被检测到,这为早期干预提供了一个潜在的窗口。尽管ctc和CECs有望作为预后生物标志物,但它们在胰腺癌中的临床应用仍未得到充分探索。微流控技术提供了罕见细胞的无标记分离,但很少有临床验证系统的基准。在这项研究中,我们将我们的惯性微流体系统与广泛使用的免疫磁阴性选择平台(EasySep™)进行了直接比较。在匹配的实验条件下,我们量化了靶细胞的恢复和富集来评估性能。与EasySep™相比,惯性微流体系统显示出更高的回收率和富集度,特别是在低细胞浓度下,这支持了其临床转化的潜力。这些发现强调了无标记微流控分离的优势及其在胰腺癌早期检测、预后评估和治疗监测方面的前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Benchmarking microfluidic and immunomagnetic platforms for isolating circulating tumor cells in pancreatic cancer

Benchmarking microfluidic and immunomagnetic platforms for isolating circulating tumor cells in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality in the US., with poor prognosis due to late-stage diagnosis and high recurrence rates following surgery. Circulating tumor cells (CTCs) are thought to contribute to post-surgical metastasis, while circulating epithelial cells (CECs) have been detected in up to 33% of patients with premalignant pancreatic cysts, offering a potential window for early intervention. Despite their promise as prognostic biomarkers, the clinical utility of CTCs and CECs in pancreatic cancer remains underexplored. Microfluidic technologies offer label-free isolation of rare cells, but few have been benchmarked against clinically validated systems. In this study, we conducted a direct comparison of our inertial microfluidic system with a widely used immunomagnetic negative selection platform (EasySep™). Using matched experimental conditions, we quantified target cell recovery and enrichment to evaluate performance. The inertial microfluidic system demonstrated higher recovery and enrichment, particularly at low cell concentrations, compared to EasySep™, supporting its potential for clinical translation. These findings highlight the advantages of label-free microfluidic isolation and its promise for early detection, prognostic assessment, and therapeutic monitoring in pancreatic cancer.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Lab on a Chip
Lab on a Chip 工程技术-化学综合
CiteScore
11.10
自引率
8.20%
发文量
434
审稿时长
2.6 months
期刊介绍: Lab on a Chip is the premiere journal that publishes cutting-edge research in the field of miniaturization. By their very nature, microfluidic/nanofluidic/miniaturized systems are at the intersection of disciplines, spanning fundamental research to high-end application, which is reflected by the broad readership of the journal. Lab on a Chip publishes two types of papers on original research: full-length research papers and communications. Papers should demonstrate innovations, which can come from technical advancements or applications addressing pressing needs in globally important areas. The journal also publishes Comments, Reviews, and Perspectives.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信